Auris tries to rebound from PhIII failure with new trial design; Kymab ties the knot with Shanghai-based EpimAb
Two months after its shares were crushed in a rout following the failure of a key late-stage study of its tinnitus treatment, Auris Medical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
